BA
BOLD

BlackRock Advisors’s Audentes Therapeutics, Inc BOLD Stock Holding History

BlackRock Advisors’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$3.72M Buy
203,621
+3,549
+2% +$61.3K ﹤0.01% 1250
2016
Q3 		$3.56M Buy
+200,072
New +$3.04M ﹤0.01% 1245

Other funds holding BOLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

BlackRock Advisors's BOLD Position: Q4 2016 in Review

BlackRock Advisors increased its Audentes Therapeutics, Inc (BOLD) stake by 1.8% in Q4 2016, buying an estimated $61.3K and bringing the position to 203,621 shares worth $3.72M. The position accounts for ﹤0.01% of the portfolio, ranked #1250.

BlackRock Advisors first reported a position in BOLD in Q3 2016 and has held it in 2 quarters since. 57 funds tracked by Wall St. Rank hold BOLD as of Q4 2016.

  • BlackRock Advisors held 203,621 shares of Audentes Therapeutics, Inc worth $3.72M as of Q4 2016.
  • BlackRock Advisors bought 3,549 Audentes Therapeutics, Inc shares in Q4 2016, an estimated $61.3K.
  • Audentes Therapeutics, Inc made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1250 holding.
  • BlackRock Advisors first reported a position in Audentes Therapeutics, Inc in Q3 2016 and has held it in 2 quarters since.
  • 57 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.